Roche Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living with Overweight and Obesity
Most insurance providers classify anti-obesity medications as "cosmetic drugs." Ridiculous we know
For example, employers must assess the effectiveness of benefit provisions, programs and vendors offered, eliminating those that deliver less value, while employees can find cost-effective ways to get their recommended screenings and immunizations and use health plan resources and navigation tools to find providers that deliver high-value care
Your doctor may order a CT scan to confirm a diagnosis of diverticulitis
In September 2025, Eli Lilly canceled one of its two Phase 2 bimagrumab trials, though the company cited strategic business reasons rather than safety signals, and a second trial in non-diabetic obesity patients continued
Unlike melatonin , which primarily signals sleep timing to your circadian system, DSIP appears to modulate sleep depth and quality
-1775582746855.png&w=384&q=75)
